Cyramza 100 mg/10 mL (10 mg/mL)
CYRAMZA is a clear to slightly opaque and colorless to slightly yellow infusion concentrate contained in a rubber-capped glass vial. Each vial of CYRAMZA 100 mg/10 mL infusion concentrate packaging may contain one or two vials. Not all packaging sizes may be available.
CYRAMZA is an anticancer medication that contains the active ingredient ramucirumab, a monoclonal antibody. This customized protein can recognize and bind to another protein called "VEGF receptor 2" found on blood vessels. This receptor is necessary for the development of new blood vessels, which are essential for the growth of cancer. By binding to and blocking "VEGF receptor 2," the medication interrupts the blood flow to cancer cells.
CYRAMZA is administered in combination with another anticancer drug, paclitaxel, for the treatment of advanced stage gastric cancer (or junctional cancer between the esophagus and stomach) in patients with Eastern Cooperative Oncology Group (ECOG) performance scores of 0-1, whose disease has worsened following treatment with other cancer therapies.
Cyramza 100 mg/10 mL (10 mg/mL) You can contact us to find out the price:
Contact for detailed information